drugset / Trial / NCT00215202
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Phase 2
Completed
16 enrolled
Dartmouth-Hitchcock Medical Center
AstraZeneca · collabDana-Farber Cancer Institute · collabKentuckiana Cancer Institute · collabM.D. Anderson Cancer Center · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The use of Iressa will result in a greater than 20% response rate in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy).
Timeline
- Start
- 2004-08
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |